LexaGene’s beta prototype achieves 98.2% consistency with reference lab data

LexaGene Holdings, Inc., a biotechnology company that develops genetic analyzers for rapid pathogen detection and other molecular markers, announced today the test results from its first beta prototype placed at the Massachusetts Veterinary Referral Hospital in Woburn, MA. Mass Vet is one of 24 hospitals owned and operated by Ethos Veterinary Health. LexaGene’s beta prototype achieves 98.2% consistency with reference lab data